Stanford’s Professor John Cooke Joins Pluristem’s Scientific Advisory Board
Business Wire
posted: 2 DAYS 1 HOUR AGOPrintShareText SizeAAAPluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that John Cooke, MD, PhD has accepted an appointment to the Company’s Scientific Advisory Board to assist Pluristem with its efforts to further develop the Company’s product candidates and give patients a better chance.
Dr. Cooke, Professor of Medicine, Division of Cardiovascular Medicine at the Stanford School of Medicine, as well as Associate Director (Education and Training) of Stanford’s Cardiovascular Institute in Palo Alto, California, said: “Scientific discoveries of today are the medicine of tomorrow. I am pleased to join Pluristem’s Scientific Advisory Board, since I believe that the scientists and management team at Pluristem use innovative approaches to make breakthrough discoveries in the cell therapy arena as well as to build a biotechnology company with sound business values.”
Zami Aberman, Pluristem’s President and CEO, said: "We are proud that Dr. Cooke has accepted a position on what has become a world renowned Scientific Advisory Board at Pluristem. Dr. Cooke’s expertise in angiogenesis and wound-care will create significant synergism together with the knowledge and expertise of our current Board members.”
Dr. Cooke received his MD degree from Wayne State University, Detroit, and his PhD from the Mayo Graduate School of Medicine, Rochester, MN, and was a faculty member of Harvard Medical School prior to his recruitment to Stanford University. He serves on the editorial boards of several cardiovascular journals including Circulation, and is past-president of the Society for Vascular Medicine. Dr. Cooke’s area of research interest is in angiogenesis and he has served as the Principal Investigator for numerous clinical trials.
Detailed biographies of each member of the Advisory Board are available on our website at: Pluristem’s Advisory Board, the content of which is not part of this press release. |
